News & Events

At the FIGON Dutch Medicines Days, the RSNN session brought together different perspectives on what it takes to remain an attractive country for clinical research. A clear message emerged: attracting clinical research is about much more than speed. Read the main take aways from our speakers and download their presentations. 

Early access programmes play an important role in providing patients with unmet medical needs access to innovative treatments. On 19 May 2026, the Regulatory Science Network Netherlands (RSNN) brought together experts from different stakeholder groups to discuss challenges and opportunities for improving early access to medicines in the Netherlands.

As medicines, technologies and research methods continue to evolve, regulatory frameworks must keep pace. In order to support this developing field, in May 2025, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) launched the European Platform for Regulatory Science Research. 

On 17 November, the RSNN Special Interest Group (SIG) ATMP will organise a meeting at Villa Jongerius in Utrecht from 09:30 to 12:45. The meeting will be followed by lunch.

Registration for the RSNN Annual Workshop 2026: "Aligning HTA and Regulatory Decision-Making: Comparative Evidence in a Changing European Landscape" is now open. The event will take place on 17 November 2026 in person at Villa Jongerius in Utrecht.

In 2025, RSNN celebrated its 10-year anniversary. In the Annual Report, we are presenting an overview of the activities and achievements of RSNN in 2025. 

On Thursday 11 September 2025, a Regulatory Science Network Netherlands (RSNN) Expert Meeting was held with a total of twenty-six participants with diverse expertise from nine different European countries. During the meeting the potential of the European Platform for Neurodegenerative Diseases (EPND) was discussed. 

On December 9th, the masterclass 𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 – 𝗧𝗵𝗲 𝗡𝗔𝗠𝘀 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲  on New Approach Methodologies (NAMs) brought together scientists, regulators, industry leaders and innovation networks to discuss how scientific advances can accelerate safer, more effective, and increasingly animal-free drug development.

The full report of the RSNN Annual Workshop titled "Single Arm Trials”, which took place on 18 November 2025 is now available.

In 2025, the Regulatory Science Network Netherlands (RSNN) marked its ten-year anniversary. 

On November 18th, RSNN celebrated its 10 year anniversary during the Annual Workshop.  The Annual Workshop focused on Single Arm Trials with its benefits and challenges.  

The RSNN Special Interest Group Advanced Therapies Expert Meeting on in vivo gene editing took place on Tuesday 15 July 2025.

On 9 October RSNN organized a parallel session at the FIGON Dutch Medicines Days on the topic "Patient Access to Unregistered Medicines: Current Developments in Compassionate Use" (Abstract). The slides presented during this session are now available for download.

As of 2025, Rick Vreman (Policy Lead and Head of Access Operations at Roche Netherlands) has been appointed as co-chair of the RSNN. He is replacing Sjaak Bot, who retired last year, as representative of the industry stakeholder group. We spoke with Rick about his background, the RSNN, and his new position.

Op woensdag 12 maart 2025 vond de opvolgende RSNN Expert meeting “Klinisch onderzoeksklimaat in Nederland: Reflectie en vooruitblik op het Nationaal Actieplan Klinisch Onderzoek” plaats. Een groep van 26 experts kwam bijeen om te reflecteren op het Nationaal Actieplan Klinisch Onderzoek.